5767-36-2

Basic information

• Product Name: 4-(6-Hydrazino-4-pyriMidinyl)Morpholine, 96%
• Synonyms: 4-(6-Hydrazino-4-pyriMidinyl)Morpholine, 96%;4-(6-Hydrazinyl-4-pyrimidinyl)morpholine;4-(6-Hydrazinopyrimidin-4-yl)morpholine;4-(6-Hydrazinylpyrimidin-4-yl)morpholine
• CAS NO: 5767-36-2
• Molecular Formula: C8H13N5O
• Molecular Weight: 195.22172
• Mol File: 5767-36-2.mol
• Article Data: 6

Chemical Properties

• Melting Point: 162-163℃
• Appearance: /
• CAS DataBase Reference: 4-(6-Hydrazino-4-pyriMidinyl)Morpholine, 96%(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(6-Hydrazino-4-pyriMidinyl)Morpholine, 96%(5767-36-2)
• EPA Substance Registry System: 4-(6-Hydrazino-4-pyriMidinyl)Morpholine, 96%(5767-36-2)

Safety Data

• Hazardous Substances Data: 5767-36-2(Hazardous Substances Data)

Usage

General Description

4-(6-Hydrazino-4-pyriMidinyl)Morpholine, 96% is a chemical compound with a purity of 96%. It has the molecular formula C8H14N6O and a molecular weight of 214.24 g/mol. 4-(6-Hydrazino-4-pyriMidinyl)Morpholine, 96% is a heterocyclic compound that contains both a morpholine and a pyrimidine ring. It is commonly used in organic synthesis as a building block for the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. It is also used as a reagent in the preparation of various heterocyclic compounds. Additionally, it plays a role as a key intermediate in the synthesis of potential anti-cancer agents and antiviral drugs, making it a valuable chemical in the pharmaceutical industry.

Upstream product

• 110-91-8 morpholine 
• 5767-35-1 6-chloro-4-hydrazinopyrimidine 
• 1193-21-1 4,6-dichloropyrimidine 
• 22177-92-0 4-(6'-chloropyrimidin-4'-yl)morpholine 

Downstream Products

• 1375799-59-9 sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate 

Relevant articles and documents

Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia

Small-molecule inhibitors of hypoxia-inducible factor prolyl hydroxylases (HIF-PHs) are currently under clinical development as novel treatment options for chronic kidney disease (CKD) associated anemia. Inhibition of HIF-PH mimics hypoxia and leads to increased erythropoietin (EPO) expression and subsequently increased erythropoiesis. Herein we describe the discovery, synthesis, structure–activity relationship (SAR), and proposed binding mode of novel 2,4-diheteroaryl-1,2-dihydro-3H-pyrazol-3-ones as orally bioavailable HIF-PH inhibitors for the treatment of anemia. High-throughput screening of our corporate compound library identified BAY-908 as a promising hit. The lead optimization program then resulted in the identification of molidustat (BAY 85-3934), a novel small-molecule oral HIF-PH inhibitor. Molidustat is currently being investigated in clinical phase III trials as molidustat sodium for the treatment of anemia in patients with CKD.

SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS

The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES

-